These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9332680)

  • 1. Randomized study of zorubicin versus zorubicin-cisplatin in undifferentiated carcinoma of the nasopharynx (UCNT).
    Jelić S; Kovcin V; Milanović N; Kreacić M; Pendjer I; Jovanović V; Ristović Z; Oprić M; Mitrović L
    Ann Oncol; 1997 Aug; 8(8):739-44. PubMed ID: 9332680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults].
    Jelić S; Tomasević Z; Kreacić M; Kovcin V; Radosavljević D; Vlajić M
    Bull Cancer; 1996 Dec; 83(12):1002-7. PubMed ID: 9116363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
    Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
    Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
    Hasbini A; Mahjoubi R; Fandi A; Chouaki N; Taamma A; Lianes P; Cortès-Funes H; Alonso S; Armand JP; Cvitkovic E; Raymond E
    Ann Oncol; 1999 Apr; 10(4):421-5. PubMed ID: 10370784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
    Jelić S; Stamatović Lj; Vucićević S; Petrović Z; Kreacić M; Babović N; Jovanović N; Mikić A; Gavrilović D
    Eur J Cancer; 2002 Jul; 38(11):1478-89. PubMed ID: 12110494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of acute leukemia in the adult. Role of anthracyclines].
    Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
    Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin-cisplatin and radiotherapy.
    Pendjer I; Krejovic B; Vucicevic S
    Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S127-9. PubMed ID: 9065646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role?
    Martoni A; Guaraldi M; Piana E
    Ann Oncol; 1999; 10 Suppl 5():S19-23. PubMed ID: 10582134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
    Pignon B; Witz F; Desablens B; Leprise PY; Francois S; Linassier C; Berthou C; Caillot D; Lioure B; Cahn JY; Casassus P; Sadoun A; Audhuy B; Guyotat D; Briere J; Vilque JP; Baranger L; Polin V; Berthaud P; Hurteloup P; Herve P; Harousseau JL
    Br J Haematol; 1996 Aug; 94(2):333-41. PubMed ID: 8759894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.